Our study showed that anti-TIM-3 and anti-PD-1 therapy could inhibit the occurrence of HPD in a treatment-naïve mouse model and reverse the tumor progression in the established HPD mouse model induced by anti-PD-1 monotherapy. Here, HAVCR2 is linked to neoplasm.